Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous relationship with telehealth company Hims & Hers Health (NYSE: HIMS) in the past year would be a bit of an understatement. The two companies have gone from working together to Novo Nordisk suing Hims & Hers. Most recently, however, they have announced a deal where Hims & Hers Health will be able to sell Novo Nordisk's popular GLP-1 drugs, Ozempic and Wegovy. Finally, it looks as though the drama involving the two companies may be ending. And here's why that can be great news for investors in both of these companies. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. The arrangement makes sense for both sides Under the new agreement, Hims & Hers will be able to sell Ozempic and Wegovy to its customers, i
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- When generic versions of weight-loss drugs arrive, public plans should cover them, experts say [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA: Novo Nordisk failed to report deaths of weight-loss drug patients [USA TODAY]USA TODAY
- Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Faces Legal Probe As Trial Setback Reshapes Risk Expectations [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website